Introduction
It is now generally accepted that the administration of Rh-immune globulin to susceptible mothers at delivery may result in almost complete suppression of antibody formation in Hematology Research Unit, University of Alberta Hospital, Edmonton, Alberta.
f Canadian Red Cross Blood Transfusion Service, Edmonton, Alberta. the postpartum period (Brit. med. 7., 1966; Freda, Gorman, and Pollack, 1966; Zipursky and Israels, 1967;  Mollison, 1968) .
Investigation into the prevention of Rh sensitization has been carried on in Edmonton since January 1967 as part of a co-operative study involving the western Canadian provinces (Canad. med. Ass. 7., 1967; Chown, 1967) . Our part in the study was designed primarily to compare the effectiveness of two different doses of Rh-immune globulin and to try to establish a minimum effective dose. However, we were also interested in trying to establish the incidence of sensitization during the last trimester of pregnancy. Our interest was stimulated by the fact that in northern Alberta from 1965 to 1967 3.5% of women with anti-D agglutinins found in the last trimester of pregnancy were primigravidae.
Methods and Materials

Selection of Subjects
Criteria for entry into the study were: (a) Rh-negative mother of any parity with an Rh-positive husband; (b) no anti-D when first tested during pregnancy; and (c) delivery of an Rh-positive ABO-compatible infant.
The following tests were done on all of the possible candidates for the study: ABO and Rh phenotype of the mother, ABO Table I ). 
Study Group
Of the 444 in the study 361 were treated and 83 were untreated (see Table I ). The treated cases received an injection of either 0.5 ml. (145 ,ug. anti-D) or 1.5 ml. (435 ,ug. anti-D) of Rh-immune globulin* within 48 hours after delivery. These were given in an alternate fashion in an attempt to establish a minimal effective dose. Gorman's data, as quoted by Zipursky and Israels (1967) , suggests that the minimum effective dose may be less than 100 ,ug. of anti-D.
Seventy of the 83 untreated subjects were delivered before the availability of Rh-immune globulin and were included as untreated controls. The remaining 13 included nine who objected to the injections but agreed to appear for follow-up blood tests at six weeks and six months. The other four were found at delivery to have titres of anti-D varying from 1: 8 to 1: 64, and produced infants with positive direct Coombs tests on cord blood. These subjects were not treated but were retained for further study.
Antibody-testing
The sera of the mothers included in the study were tested (a) at delivery, (b) 48 hours after delivery, (c) six weeks after delivery, and (d) six months after delivery.
These sera were tested with the following known cells:
(1) O, RIR2 cells pretreated with 1% ficin; (2) (Buchanan, 1956; Buchanan and Dierich, 1965) ; and (5) Details of these cases are given in Tables III and IV . The subjects in Table III were untreated, while those in Table IV were treated within 48 hours after delivery with either 0.5 or 1.5 ml. of Rh-immune globulin. Four of the untreated group and one of the treated group had antibody titres with ficinand protease-G-treated cells of from 1: 8 to 1: 64 when tested at delivery. Their infants showed weak but definite positive direct Coombs tests on cord blood. The others had weak antibodies at delivery, detected only with the enzyme-treated deletion cells. 
Results of Treatment
Subjects Negative for Antibody at Delivery Table V shows the results of follow-up in the group without detectable antibodies at delivery. Seventy subjects were untreated. Forty-two of these were followed to six months, and two (4.8%) were found to have detectable antibodies. These antibodies were not strong, being recorded as positive only in the first tube of the titration with the enzyme-treated D--/D--cells; nevertheless, they had anti-D specificity. 
Subjects Positive for Antibody at Delivery
Twenty-nine subjects showed antibody at the time of delivery (Table II) . Thirteen were untreated (Table III) , and 16 were treated (Table IV) .
Four of the cases showing strong antibody were in the untreated group and at six months had a persistence of high antibody levels. The fifth case (No. 28) was treated with 0.5 ml.
of Rh-immune globulin and has not yet been followed to six months. At six weeks, however, she had an antibody titre of 1:128, a level much higher than would be expected from the administration of 0.5 ml. of passive antibody alone, and at six months the titre is 1: 256. (1967) and Cohen and Zuelzer (1964) (1964) , working with guinea-pigs, found that the first antibody produced in response to an antigen was a gamma-M gammaglobulin, and that it was followed in three to four days by the production of gamma-G globulin. If gamma-G gammaglobulin which contained antibody specific for the antigen was given after the onset of gamma-M production, but before gamma-G antibody was detectable, then further antibody response was suppressed. If, however, the injection was given after gamma-G was detectable it was ineffective in suppressing further antibody production. Wigzell (1966) has gone a step further and has shown that passively administered antibody, given as late as 20 days after a primary stimulus, could still inhibit the production of gamma-G antibody. On this evidence it is interesting to speculate that the antibody found at delivery in the treated subjects who were later negative for anti-D was a gamma-M antibody, and that the Rh-immune globulin was effective because it was given before the onset of gamma-G production.
There are two possible explanations for the persistence of antibody in spite of treatment in Case 23 (Table IV) . Firstly, the stage of gamma-G production may have been reached before the injection was given. Secondly, the 0.5 ml. dose of Rhimmune globulin may have been inadequate.
Of interest were the subjects who had evidence of sensitization at delivery, were untreated, and yet became negative for anti-D by six months. If the weak antibody which was found at delivery indicated a primary immune response to the D antigen the subsequent disappearance of the antibody may merely mean that it dropped to a level which was below the sensitivity of our tests. If so, with re-exposure to the D antigen -that is, another Rh-positive foetus, an exaggerated anti-D response typical of a secondary immune reaction may occur. These subjects will be carefully followed in a subsequent pregnancy for evidence of this. In 
Antenatal Treatment
The work of Zipursky and Israels (1967) indicates that giving anti-D gammaglobulin intramuscularly during pregnancy is a safe procedure and that the anti-D given has no detrimental effect on the Rh-positive foetus. With this encouragement, we are now embarking on an antenatal treatment programme.
All Rh-negative women who have Rh-positive husbands and who have no detectable anti-D will be given 0.5 ml. (145 ,ug. anti-D) of Rh-immune globulin at 34 weeks' gestation. A further 0.5 ml. will be administered on delivery of an ABOcompatible Rh-positive infant. This programme will be compared with more conventional treatment with either 0.5 or 1 ml. of Rh-immune globulin given only at delivery.
Introduction
The use of living influenza viruses as vaccines has many advantages. The vaccines are quickly and painlessly administered as drops or spray and induce a high degree of immunity (Beare et al., 1968) . However, many problems arise in their preparation. In our hands the Russian A2 virus Iksha failed to infect after a few passes in the laboratory, and this was attributed to the effects of egg passage (Zhdanov et al., 1957; Beare et al., 1967) . Burnet and Bull (1943) originally suggested that influenza viruses were inherently genetically unstable and that it might be possible to attenuate them by egg passage so that they could be used as living vaccines. This has now been said in more precise terms by Zhdanov (1967) , who maintains that passage in embryonated eggs induces first a rapid loss of human pathogenicity and later a loss of human infectivity. He adds that the number of passes needed for these changes varies rather widely with different virus strains, and that the changes themselves can be detected only in volunteer trials, since there are no reliable laboratory markers by which they can be predicted. Our own subsequent experience with influenza B viruses, however, indicated that these were
